Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

2.75
-0.0950-3.35%
Volume:290.46K
Turnover:802.76K
Market Cap:72.14M
PE:-1.26
High:2.87
Open:2.84
Low:2.74
Close:2.84
52wk High:16.00
52wk Low:2.66
Shares:26.28M
Float Shares:19.19M
Volume Ratio:1.67
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1721
EPS(LYR):-2.5842
ROE:-774.56%
ROA:-77.88%
PB:9.09
PE(LYR):-1.06

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex

Reuters
·
Jun 16

Top Midday Decliners

MT Newswires Live
·
Jun 16

Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal

Reuters
·
Jun 15

Elicio selloff brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Jun 15

Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan

TIPRANKS
·
Jun 15

Elicio Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 15

Elicio Therapeutics Shares Fall After Missing Primary Endpoint in Pancreatic Cancer Trial

MT Newswires Live
·
Jun 15

Elicio Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $23 From $17

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics Shares Fall 50% Premarket After Co Reports Mid-Stage Data for Its Experimental Pancreatic Cancer Therapy

THOMSON REUTERS
·
Jun 15

BUZZ-Elicio Therapeutics tumbles as pancreatic cancer vaccine misses main goal of trial

Reuters
·
Jun 15

Elicio says Phase 2 AMPLIFY-7P trial of ELI-002 7P misses primary DFS endpoint in adjuvant pancreatic cancer

Reuters
·
Jun 15

Elicio Therapeutics - Eli-2 7P Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics Reports Results From Phase 2 Amplify-7P Study and Outlines Refined Phase 3 Development Strategy for Eli-002 7P in Adjuvant Pancreatic Cancer

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - Evaluating Strategic Financing and Partnering Opportunities

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - to Focus Phase 3 Development on R0 Resected Population With Additional Eli-2 7P Dosing

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - Amplify-7P Phase 2 Study Does Not Meet Primary Dfs Endpoint in Intent-to-Treat Population

THOMSON REUTERS
·
Jun 15

U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology

Reuters
·
Jun 15

Elicio Therapeutics Initiated at Buy by B. Riley Securities

Dow Jones
·
Jun 11

U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle

Reuters
·
Jun 10

Elicio Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $27

THOMSON REUTERS
·
Jun 10